Decrease in METH-evoked DA release in the nucleus accumbens in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

NAS (NAFLD Activity Score) of liver tissue of mice in each group after 8 weeks of treatment with either vehicle (V) or Kylo-0603 (0.1-10 mg/kg/day). by Xueqin lu (22250795)

Subjects:

Decreases in locomotor responses to a single METH injection in <i>Ptprz</i>-KO mice. by Akihiro Fujikawa (122649)

<i>STN1</i> suppression decreases cell viability upon hydrogen peroxide treatment. by Tomohiko Hara (14980890)

The Karolinska Sleepiness Scale (KSS) is a 9-point Likert scale, ranging from “extremely 1 = alert” to “9 = extremely sleepy–fighting sleep” [44]. by Marcel F. Hinss (14675457)

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the neck-specific exercise with internet support (NSEIT) group and t... by Anneli Peolsson (7867601)

Subjects:

Plot of influential SST data points from daily SST measurements of the MHI. by Rebecca J. Ward (9872202)

Hematoxylin and eosin (H&E) staining, Sirius Red staining, and Oil Red staining of liver tissues from mice in each group after 8 weeks of treatment with either vehicle or Kylo-0603... by Xueqin lu (22250795)

Subjects:

Tamoxifen-induced Cre-mediated hematopoietic loss of <i>Zeb1</i> leads to decreased hematopoietic colony formation potential in adult BM as well as altered T-cell differentiation. by Jueqiong Wang (11467505)

“…<b>(C)</b> HSPCs isolated from <i>Zeb1</i>^<i>Δ/Δ</i> BMs show decreased numbers of colonies in methylcellulose-based colony assays at the first plating that further decreases at the first (replate1) and secondary replating (replate2) compared to Cre negative controls. …”

Higher reward decreases three measures of response variability. by Zvi N. Roth (9611598)

The <i>E</i>. <i>multilocularis</i> antigen-specific IgG reactivity (OD) in alveolar echinococcosis (AE) patients and infection-free controls. by Beate Grüner (301524)

Overall and sex-stratified paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

S1 Graphical abstract - by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by census regions in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000 in adults in the metropolitan and non-metropolitan areas in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by race in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related age-adjusted mortality rates per 100,000, stratified by age groups in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Paroxysmal tachycardia-related deaths and age-adjusted mortality rates per 100,000, stratified by state in adults in the United States, 1999 to 2020. by Aman Goyal (19231397)

Subjects:

Fig 1 - by Martin Wasserbauer (6239699)

Subjects:

Changes in the melting points of each formulation of 0.1% FLU ophthalmic suspensions. by Tokio Obata (10783047)

Subjects: